Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29996541 | 1.00 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.82 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31072600 | 0.82 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31733654 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL29400520 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3060297 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL27143076 | 0.80 | FABP5 (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15119354 | 0.80 | KMT2A (0.60) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29401144 | 0.79 | CASP3 (0.48) | KMT2AEPHX2CASP3 | |
| SCHEMBL7650015 | 0.79 | CASP3 (0.48) | KMT2AEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181249-A | Electron-withdrawing group functionalized hypercrosslinked polymer and preparation method and application thereof | 中南民族大学 | 2022-10-14 | — | — | CN | claimed |
| EP-1498978-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | UBE INDUSTRIES (JP) | 2010-09-08 | — | — | EP | claimed |
| US-7297442-B2 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD. (JP) | 2007-11-20 | — | — | US | claimed |
| US-20050255384-A1 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD (JP) | 2005-11-17 | — | — | US | claimed |
| EP-1498978-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | Ube Industries, Ltd. (JP) | 2005-01-19 | — | — | EP | claimed |
| US-5098999-A | Amidation of amino acids like dopa for use as adhesives and for treatment of Parkinson*s disease | HITACHI CHEMICAL COMPANY (JP) | 1992-03-24 | — | — | US | claimed |
| CN-115181249-A | Electron-withdrawing group functionalized hypercrosslinked polymer and preparation method and application thereof | 中南民族大学 | 2022-10-14 | — | — | CN | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3782220-A1 | AN ELECTROLYTE COMPOSITION FOR A LITHIUM-ION BATTERY AND A LITHIUM-ION BATTERY | Karlsruher Institut für Technologie (DE) | 2021-02-24 | — | — | EP | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-5965524-A | BIOSURFACTANTS, ANTIBACTERIAL, ANTIVIRAL AND ANTITRYPANOSOMAL THERAPEUTIC COMPOUNDS | PEPTIDE TECHNOLOGIES CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0400972-B1 | Fluorescent degree of cure monitors | MINNESOTA MINING & MFG (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5182316-A | Forming a UV-detectable fluorophore in a mixture of hydride containing silicone, unsaturated silicone, cationically sensitive compound and a latent dibenzofulvene | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-01-26 | — | — | US | disclosed |
| US-5118559-A | Dibenzofulvene compound | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5098999-A | Amidation of amino acids like dopa for use as adhesives and for treatment of Parkinson*s disease | HITACHI CHEMICAL COMPANY (JP) | 1992-03-24 | — | — | US | disclosed |
| US-5047444-A | Hydrosilatable polysiloxanes, unsaturated compounds and a dibenzofulvene chromogen; coatings | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0400972-A2 | Fluorescent degree of cure monitors | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | KMT2A 2821/4885FABP5 1792/4885FABP7 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.